Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.05 CAD
Change Today +0.01 / 25.00%
Volume 10.0K
VPT On Other Exchanges
As of 1:42 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

ventripoint diagnostics ltd (VPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/27/15 - C$0.09
52 Week Low
12/9/14 - C$0.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ventripoint diagnostics ltd (VPT) Related Businessweek News

No Related Businessweek News Found

ventripoint diagnostics ltd (VPT) Details

VentriPoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools to monitor patients with heart disease. The company offers Ventripoint Medical System that is used to generate critical volume and functional measurements of the right ventricle. VentriPoint Diagnostics Ltd. is based in Bellevue, Washington.

ventripoint diagnostics ltd (VPT) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $224.6K
Chief Financial Officer
Total Annual Compensation: $97.8K
Vice President of Clinical Affairs and Develo...
Total Annual Compensation: $145.8K
Compensation as of Fiscal Year 2014.

ventripoint diagnostics ltd (VPT) Key Developments

VentriPoint Diagnostics Ltd., Special/Extraordinary Shareholders Meeting, Sep 28, 2015

VentriPoint Diagnostics Ltd., Special/Extraordinary Shareholders Meeting, Sep 28, 2015.

Ventripoint Diagnostics Ltd. Announces New Platform Design of VMSTM Workstation

Ventripoint Diagnostics Ltd. announced that a new platform design of the VMSTM workstation will be made available to select markets with complete availability expected in the 4th quarter of 2015. The new platform, branded VMS-PlusTM, was the Company's featured product at the American Society of Echocardiography Scientific Session (ASE 2015) held in Boston last week. VMS-Plus will replace the current cart-based platform and has features that include improved ergonomics, less physical space to operate, and increased portability. The VMS-Plus was well received at the ASE 2015 by those individuals familiar with the original VMS machine. They particularly liked the sleek design and the enhanced feature being tested that corrects for patient movement that may occur during the exam. This feature has been the single most requested enhancement from its customer base. With the recent clearance in the United States of the Right Ventricle (RV) database for all patients where RV analysis is desired or warranted, the Company has been encouraged to make commercially available databases for the other 3 chambers of the heart. While RV volume measurements are valuable in chronic heart failure, there is a large demand for accurate volume measurements of the Left and Right Atria for treating patients who have pacemakers as well as those with heart failure. The VMS is ideally suited to provide these measurements quickly and with the accuracy of MRI, which remains the gold standard for cardiac chamber volumes but is not done routinely due to cost and convenience. A first look at the process for VMS volume quantification in all 4 chambers of the heart was also exhibited at ASE 2015. This feature was demonstrated recently at one of China's most prestigious cardiac care hospitals, Anzhen Hospital in Beijing, where it was very well received and recognized as addressing an emerging need. This demonstration makes the VMS the world's first technology to provide 3D volume quantification of all 4 heart chambers using 2D ultrasound, which is the most common method for cardiac exams in the world. The VMS technology can also provide analysis of 3D ultrasound images of the heart with the same accuracy as MRI. This is a benefit to the market as current 3D ultrasound technology is widely accepted as inaccurate in calculating volumes. Initially thought to be years away, Ventripoint is hopeful that all development will be completed for the 4 chamber feature within this year, followed by regulatory clearances and commercial release. In addition to the new workstation design for the VMS-Plus, another new VMS platform has been created for Ventripoint's product line. This product has been designed specifically for emerging markets in order to offer great value in a very compact design. The new VMS product is expected to be Ventripoint's lead-in to emerging markets where low-cost, 2D-ultrasound equipment is prevalent. The Company is currently seeking manufacturing partners for this model.

VentriPoint Diagnostics Ltd. Receives Marketing Clearance from the FDA for the Expanded Indications for Use of its VMS(TM) Product

Ventripoint Diagnostics Ltd. announced that it has received Marketing Clearance from the U.S. Food & Drug Administration ("FDA") for the expanded Indications for Use of its VMS(TM) product which states; "The VMS system is indicated for use where RV (right ventricle) volumes and ejection fractions are warranted or desired". The information about the function of the RV is known to predict the course of heart disease and can be used by the cardiologist to determine how frequently to evaluate the patient. Heart disease remains the leading cause of death globally with the RV being the determining factor for the vast majority of patient outcomes. The only comparable method used with cardiac ultrasound to assess RV function is real-time 3D echocardiography, which is widely accepted as being inaccurate in terms of volumetric data. Other methods of obtaining functional RV data are inconvenient and can take hours (MRI) or involve high doses of radiation (CT scan). Further, both MRI and CT scan may require the injection of contrast media, which can be detrimental in patients with concerns for kidney failure. The use of VMS overcomes all of the concerns related to MRI and CT, from the most widely used method in the world for heart evaluation, that being 2D Echo. This remains the exam modality of choice as it is convenient, inexpensive, and fast, all of which are benefits gained when using the VMS.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VPT:CN C$0.05 CAD +0.01

VPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VPT.
View Industry Companies

Industry Analysis


Industry Average

Valuation VPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 54.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 48.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENTRIPOINT DIAGNOSTICS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at